# Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

> **NCT00111475** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 45 (actual)

## Conditions studied

- Idiopathic Thrombocytopenic Purpura

## Interventions

- **DRUG:** Romiplostim
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00111475
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07-01
- **Primary completion:** 2004-06-17
- **Final completion:** 2004-06-17
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2020-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00111475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00111475, "Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00111475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*